Non-small-cell lung carcinoma

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

Thursday, January 14, 2021 - 4:00am

This is the third approval in China for tislelizumab, and its first in a lung cancer indication.

Key Points: 
  • This is the third approval in China for tislelizumab, and its first in a lung cancer indication.
  • Tislelizumab is being investigated in a broad clinical program, including five Phase 3 trials in lung cancer indications.
  • We are grateful to have a new treatment available in the front-line setting for patients with advanced squamous non-small cell lung cancer, said Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
  • The China National Medical Products Administration (NMPA) has granted tislelizumab full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy.

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis 2019-2020 & 2029 - 29 Late-stage Pipeline Agents are Going to Enter the NSCLC Market

Wednesday, January 13, 2021 - 8:15pm

DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women.
  • 29 late-stage pipeline agents are going to enter the NSCLC market from 2019 onwards.
  • Topline NSCLC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Wednesday, January 13, 2021 - 2:00pm

This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.

Key Points: 
  • This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.
  • The Company also reported the completion of the manufacturing scale-up for the clinical-grade production of REQORSA , subject to final testing that was underway.
  • From there, REQORSA supply will be delivered to the clinical trial sites pending FDA clearance to commence the clinical trials.
  • The Companys lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung Cancer

Wednesday, January 13, 2021 - 1:00pm

New Data from Rare EGFR Alterations;

Key Points: 
  • New Data from Rare EGFR Alterations;
    Trastuzumab deruxtecan in HER2 mutated metastatic non-small cell lung cancer; interim results of DESTINY-Lung01 (ENCORE)
    Smit, et al.
  • Each ADC is engineered using Daiichi Sankyos proprietary and portable DXd ADC technology to target and deliver chemotherapy inside cancer cells that express a specific cell surface antigen.
  • In May 2020, ENHERTU received a Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) for gastric cancer, including GEJ adenocarcinoma.
  • The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer.

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

Tuesday, January 12, 2021 - 9:01pm

National Cancer Center (NCC) Japan has agreed to provide RNA sequencing, funded in part by Merus, for eligible patients with pancreatic adenocarcinoma and patients with NSCLC to identify NRG1 fusions.

Key Points: 
  • National Cancer Center (NCC) Japan has agreed to provide RNA sequencing, funded in part by Merus, for eligible patients with pancreatic adenocarcinoma and patients with NSCLC to identify NRG1 fusions.
  • NCC Japan, established in 1962, is a leading medical institution in cancer treatment and research in Japan.
  • NCCHE, established in 1992, is one of the leading specialized cancer hospitals in Japan, treating over 9,000 new patients each year.
  • The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis to 2029 - ResearchAndMarkets.com

Tuesday, January 12, 2021 - 12:47pm

The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women.
  • Of total lung cancer incident cases, approximately 85% are the NSCLC subtype.
  • Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting.

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Tuesday, January 12, 2021 - 8:30am

Lugano, Switzerland, January 12, 2021 Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.

Key Points: 
  • Lugano, Switzerland, January 12, 2021 Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.
  • In 2017, Helsinn and Taiho signed a global co-development and commercialization agreement for TAS0953/HM06.
  • Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: "We are very pleased to have dosed the first patient in this Phase 1/2 study with TAS0953/HM06.
  • TAS0953/HM06 is an oral RET inhibitor in development for advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) and other tumors which express RET gene abnormalities.

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

Thursday, January 7, 2021 - 12:04am

Immutep reported encouraging interim data from TACTI-002 at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting on 10 November 2020.

Key Points: 
  • Immutep reported encouraging interim data from TACTI-002 at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting on 10 November 2020.
  • The data from 2nd line HNSCC patients was very robust and forms an excellent basis for additional clinical development in this indication.
  • In total 40 of 110 patients with 1st line NSCLC have now been recruited in Part A of TACTI-002.
  • The study is evaluating the combination of efti with MSDs KEYTRUDA (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

Global Non-Small Cell Lung Cancer (NSCLC) Disease Insights and Market Forecasts Report 2020-2026 - ResearchAndMarkets.com

Wednesday, January 6, 2021 - 11:13am

The "Non - Small Cell Lung Cancer (NSCLC) - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non - Small Cell Lung Cancer (NSCLC) - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
  • "Non-small cell lung cancer (NSCLC) : Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of NSCLC disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for NSCLC, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.
  • This section of the report gives the overview of NSCLC disease indication in detail.
  • The section highlights the basic definition, causes and symptoms of disease and details the types of NSCLC disease.

Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer

Tuesday, January 5, 2021 - 6:00am

Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is based on randomized data from the Phase II CITYSCAPE trial.

Key Points: 
  • Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is based on randomized data from the Phase II CITYSCAPE trial.
  • Tiragolumab is also being investigated in metastatic esophageal squamous cancer (SKYSCRAPER-08) and cervical cancer (SKYSCRAPER-04), with early trials in other tumor types.
  • Blocking both pathways simultaneously with tiragolumab and Tecentriq has the potential to increase anti-tumor activity by enhancing the bodys immune response to cancer cells.
  • CITYSCAPE is a global Phase II, randomized and blinded study evaluating tiragolumab plus Tecentriq (atezolizumab) compared with Tecentriq alone in 135 patients with first-line PD-L1-positive, locally advanced unresectable or metastatic non-small cell lung cancer.